Post Market Surveillance Study of the Wingspan Stent System
Completed · Not applicable · NCT02034058
Conditions: Intracranial Atherosclerosis
At a glance
- Research payments reported, 2025
- $12,067
- U.S. investigators named
- 4
- Sites paid
- 3
- Planned or actual enrollment
- 152
About the trial
- Sponsor
- Stryker Neurovascular
- Tested
- Wingspan Stent System (device)
- Dates
- Started 2013-12; completion 2019-08
- Results posted
- Yes
The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.
From ClinicalTrials.gov, last updated 2019-12-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Stryker Corporation reported $12,067 in research payments for this study in 2025 (9 payments).
Products named: Wingspan
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Angelos A. Konstas, MD, PHD Radiology · Pasadena, CA
- John Perl II, M.D. Neuroradiology · Boise, ID
- David H. Robinson, MD Radiology · Seattle, WA
- Christopher M. Zylak, MD Interventional Radiology · Spokane, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Huntington Hospital, CA $5,660
- Benaroya Research Institute Atvirginia Mason $3,950
- Providence Health and Services $2,103
- $354
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.